Low Response Rates to Hypomethylating Agents in Chronic Myelomonocytic Leukemia
Researchers evaluated response rates to azacitidine and decitabine in patients with chronic myelomonocytic leukemia according to various sets of response criteria.
All articles by Lauren Dembeck, PhD
Combination Regimen for Pretransplant Conditioning May Improve Outcomes for Patients With Multiple Myeloma
Busulfan plus melphalan may be a viable pretreatment conditioning regimen for patients undergoing autologous hematopoietic stem cell transplantation.
Combination Therapy May Improve Outcomes in Patients With Chronic Lymphocytic Leukemia
Patients receiving idelalisib experienced longer median overall survival compared with patients receiving placebo.
Intensive Chemotherapy May Be Beneficial for Younger Patients With Myelodysplastic Syndrome
Compared with hypomethylating agents, intensive chemotherapy was associated with higher overall response and complete remission rates.
Effects of HLA Dimorphism on Clinical Outcomes of Immunotherapy in Acute Myeloid Leukemia
Patients carrying the -21M variant of HLA-B demonstrated more favorable clinical outcomes than patients carrying the -21T variant.
Improved Long-Term Outcomes After Stronger Postinduction Intensification for Acute Lymphoblastic Leukemia
Patients with rapid early response demonstrated increased event-free and overall survival when receiving augmented postinduction intensification regimens.
Cytogenetic Abnormalities Provide Prognostic Value in Predicting Acute Myeloid Leukemia Outcomes
Patients with a monosomal or complex karyotype were found to have lower rates of leukemia-free survival compared with patients with a normal karyotype.
Next post in Hematologic Cancers
